These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24062360)

  • 1. HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice.
    Shaaban AM; Purdie CA; Bartlett JM; Stein RC; Lane S; Francis A; Thompson AM; Pinder SE;
    J Clin Pathol; 2014 Feb; 67(2):161-7. PubMed ID: 24062360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
    Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
    J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
    Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
    J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
    Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
    Hicks DG; Kulkarni S
    Am J Clin Pathol; 2008 Feb; 129(2):263-73. PubMed ID: 18208807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
    Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HER2 detection methods between central and regional laboratories in Greece.
    Papadopoulos S; Kouvatseas G; Skarlos D; Malamos N; Delliou E; Saratsiotou I; Ardavanis A; Mavroudis D; Skarpidi E; Arapantoni P; Karyda I; Patakioyta F; Aravantinos G; Razis E; Fountzilas G; Kosmidis P
    Clin Breast Cancer; 2007 Oct; 7(10):784-90. PubMed ID: 18021480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
    Hicks DG; Tubbs RR
    Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for HER2 in breast cancer.
    Lewis F; Jackson P; Lane S; Coast G; Hanby AM
    Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.
    Farshid G; Armes JE; Bell R; Cummings M; Fox S; Francis G; Haswell M; Morey A; McCue G; Raymond W; Robbins P; Bilous M
    Diagn Mol Pathol; 2010 Dec; 19(4):187-93. PubMed ID: 21052003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
    Ballinger TJ; Sanders ME; Abramson VG
    Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
    Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
    Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?
    Bethune GC; Mullen JB; Chang MC
    Am J Clin Pathol; 2013 Oct; 140(4):588-92. PubMed ID: 24045558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saving lives with accurate HER2 testing.
    Ross JS
    Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
    [No Abstract]   [Full Text] [Related]  

  • 20. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
    Umemura S; Osamura RY; Akiyama F; Honma K; Kurosumi M; Sasano H; Toyoshima S; Tsuda H; Rüschoff J; Sakamoto G
    Am J Clin Pathol; 2008 Dec; 130(6):883-91. PubMed ID: 19019764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.